Post-chemotherapy and targeted therapy imaging of the chest in lung cancer
| Autor: | Mylene T. Truong, Mehmet Altan, Ioannis Vlahos, Girish S. Shroff, Brett W. Carter |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Oncology
medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Targeted therapy Immune system Carcinoma Non-Small-Cell Lung Internal medicine medicine Humans Anaplastic lymphoma kinase Radiology Nuclear Medicine and imaging Epidermal growth factor receptor Stage (cooking) Lung cancer Lung Chemotherapy biology business.industry General Medicine medicine.disease biology.protein Immunotherapy Tomography X-Ray Computed business Tyrosine kinase |
| Zdroj: | Clinical Radiology. 77:e1-e10 |
| ISSN: | 0009-9260 |
| Popis: | Non-small-cell lung cancer (NSCLC) is frequently diagnosed when it is not amenable to local therapies; therefore, systemic agents are the mainstay of therapy for many patients. In recent years, treatment of advanced NSCLC has evolved from a general approach primarily involving chemotherapy to a more personalised strategy in which biomarkers such as the presence of genomic tumour aberrations and the expression of immune proteins such as programmed death-ligand 1 (PD-L1), in combination with other elements of clinical information such as histology and clinical stage, guide management. For instance, pathways resulting in uncontrolled growth and proliferation of tumour cells due to epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements may be targeted by tyrosine kinase inhibitors (TKIs). In this article, we review the current state of medical oncology, imaging characteristics of mutations, pitfalls in response assessments and the imaging of complications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect